ASKB589 in Combination With CAPOX and Sintilimab in Patients With Advanced, and Unresectable G/GEJ Cancer.
Status:
Recruiting
Trial end date:
2026-02-10
Target enrollment:
Participant gender:
Summary
This was an open-label, phase 1/2 study to evaluate safety, tolerability, pharmacokinetics,
and antitumor activity of ASKB589 in combination with CAPOX and Sintilimab in first-line
treatment of patients with locally advanced, recurrent, or metastatic gastric and
esophagogastric junction adenocarcinoma.